Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

Study Identifier
M05-758
CT.gov Identifier
NCT00300430
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Dyslipidemia
  • Cardiovascular Disease
    • Study Drug
  • ABT-335 and rosuvastatin calcium
  • ABT-335 and atorvastatin calcium
  • ABT-335 and simvastatin
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Adult male and female subjects who voluntarily sign the informed consent. - Subject has successfully completed one of the three ABT-335, rosuvastatin, simvastatin and atorvastatin combination therapy studies.
    Exclusion Criteria:
    - Subject is using or will use investigational medications, except as approved by Abbott. - Subject has prematurely discontinued his/her initial therapy one of the prior ABT-335, rosuvastatin, simvastatin and atorvastatin calcium combination therapy studies.

    Protocol Summary

    The primary purpose of this study is to test the safety and the effects of using an

    investigational drug regimen; once daily ABT-335 (Investigational drug) administered in

    combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in

    patients with abnormal lipid levels in the blood.

    Study Locations

    Location
    Status
    Location
    Global Medical Information
    North Chicago, Illinois, United States, 60064
    Status
    Not applicable